PSMA PET scan for recurrent prostate cancer before radiation
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a special PET scan (called PSMA, which pictures prostate cancer cells) can help doctors better find any remaining or spread of prostate cancer when your PSA level is rising again. It's for people who are planning radiation therapy, and the goal is to see if the scan changes the treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer that came back after initial treatment (PSA level rising again) or you are planning salvage radiation therapy.
- Your original prostate cancer diagnosis must have been within the last 2 years.
- Your cancer must be intermediate-unfavorable or high-risk type.
- Your most recent PSA level must be under 1.0 ng/mL.
- You must be a biological male age 18 or older.
- You cannot be currently on hormone therapy (except you may have taken bicalutamide for up to 3 days before starting the study; otherwise you must have stopped it at least 6 weeks ago).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at using a PSMA PET/CT scan to better re-check cancer activity in men whose PSA has started rising after prostate removal. If you qualify, the scan may help doctors choose the next best treatment step.
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
This trial tests a targeted radiation therapy (PSMA-RLT) for men whose prostate cancer has returned after initial treatment, shown only by rising PSA levels. It aims to control the cancer without using hormone therapy.
This trial will test if a special PET scan (18F-DCFPyL) can help doctors plan your treatment with a radioactive medicine called 177Lu-vipivotide tetraxetan. You are eligible if you already qualify for that standard therapy and have had a prior PSMA PET scan showing at least one active cancer site.
This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.
This study tests a new type of PET scan (a detailed imaging test) to find out if prostate cancer has come back after treatment. You'll receive an injection of a special tracer and then have a scan that takes pictures to help doctors locate any cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.